Logo image of ENTA

ENANTA PHARMACEUTICALS INC (ENTA) Stock Fundamental Analysis

USA - NASDAQ:ENTA - US29251M1062 - Common Stock

12.73 USD
+0.6 (+4.95%)
Last: 11/21/2025, 4:30:02 PM
12.73 USD
0 (0%)
After Hours: 11/21/2025, 4:30:02 PM
Fundamental Rating

2

ENTA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. The financial health of ENTA is average, but there are quite some concerns on its profitability. ENTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENTA had negative earnings in the past year.
ENTA had a negative operating cash flow in the past year.
ENTA had negative earnings in each of the past 5 years.
ENTA had a negative operating cash flow in each of the past 5 years.
ENTA Yearly Net Income VS EBIT VS OCF VS FCFENTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.57%, ENTA is in the better half of the industry, outperforming 66.98% of the companies in the same industry.
ENTA has a Return On Equity (-116.06%) which is in line with its industry peers.
Industry RankSector Rank
ROA -30.57%
ROE -116.06%
ROIC N/A
ROA(3y)-30.73%
ROA(5y)-23.53%
ROE(3y)-63.25%
ROE(5y)-43.49%
ROIC(3y)N/A
ROIC(5y)N/A
ENTA Yearly ROA, ROE, ROICENTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

ENTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTA Yearly Profit, Operating, Gross MarginsENTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

ENTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTA Yearly Shares OutstandingENTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENTA Yearly Total Debt VS Total AssetsENTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -1.02, we must say that ENTA is in the distress zone and has some risk of bankruptcy.
ENTA has a Altman-Z score (-1.02) which is in line with its industry peers.
A Debt/Equity ratio of 0.02 indicates that ENTA is not too dependend on debt financing.
ENTA has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: ENTA outperforms 42.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -1.02
ROIC/WACCN/A
WACC11.3%
ENTA Yearly LT Debt VS Equity VS FCFENTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 5.00 indicates that ENTA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.00, ENTA is in line with its industry, outperforming 56.10% of the companies in the same industry.
A Quick Ratio of 5.00 indicates that ENTA has no problem at all paying its short term obligations.
ENTA's Quick ratio of 5.00 is in line compared to the rest of the industry. ENTA outperforms 56.85% of its industry peers.
Industry RankSector Rank
Current Ratio 5
Quick Ratio 5
ENTA Yearly Current Assets VS Current LiabilitesENTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

ENTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.11%, which is quite impressive.
EPS 1Y (TTM)30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.58%

3.2 Future

The Earnings Per Share is expected to grow by 12.96% on average over the next years. This is quite good.
Based on estimates for the next years, ENTA will show a quite strong growth in Revenue. The Revenue will grow by 18.50% on average per year.
EPS Next Y11.83%
EPS Next 2Y14.26%
EPS Next 3Y13.57%
EPS Next 5Y12.96%
Revenue Next Year-1.43%
Revenue Next 2Y0.64%
Revenue Next 3Y1.05%
Revenue Next 5Y18.5%

3.3 Evolution

ENTA Yearly Revenue VS EstimatesENTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
ENTA Yearly EPS VS EstimatesENTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ENTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ENTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTA Price Earnings VS Forward Price EarningsENTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTA Per share dataENTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

ENTA's earnings are expected to grow with 13.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.26%
EPS Next 3Y13.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ENTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENANTA PHARMACEUTICALS INC

NASDAQ:ENTA (11/21/2025, 4:30:02 PM)

After market: 12.73 0 (0%)

12.73

+0.6 (+4.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17 2025-11-17/amc
Earnings (Next)02-09 2026-02-09
Inst Owners86.4%
Inst Owner Change-7.08%
Ins Owners6.33%
Ins Owner Change-0.14%
Market Cap354.91M
Revenue(TTM)N/A
Net Income(TTM)-92.01M
Analysts83.08
Price Target19.25 (51.22%)
Short Float %10.35%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.62%
Min EPS beat(2)8.52%
Max EPS beat(2)34.72%
EPS beat(4)3
Avg EPS beat(4)13.05%
Min EPS beat(4)-14.94%
Max EPS beat(4)34.72%
EPS beat(8)5
Avg EPS beat(8)9.79%
EPS beat(12)9
Avg EPS beat(12)11.18%
EPS beat(16)10
Avg EPS beat(16)5.11%
Revenue beat(2)1
Avg Revenue beat(2)3.64%
Min Revenue beat(2)-8.27%
Max Revenue beat(2)15.55%
Revenue beat(4)1
Avg Revenue beat(4)-4.12%
Min Revenue beat(4)-20.14%
Max Revenue beat(4)15.55%
Revenue beat(8)4
Avg Revenue beat(8)-2.63%
Revenue beat(12)6
Avg Revenue beat(12)-3.16%
Revenue beat(16)6
Avg Revenue beat(16)-4.37%
PT rev (1m)9.84%
PT rev (3m)9.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.77%
EPS NY rev (1m)0.23%
EPS NY rev (3m)11.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.48
P/FCF N/A
P/OCF N/A
P/B 4.48
P/tB 4.48
EV/EBITDA N/A
EPS(TTM)-3.83
EYN/A
EPS(NY)-3.38
Fwd EYN/A
FCF(TTM)-1.56
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS2.32
BVpS2.84
TBVpS2.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.57%
ROE -116.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.73%
ROA(5y)-23.53%
ROE(3y)-63.25%
ROE(5y)-43.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 539.25%
Cap/Sales 31.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5
Quick Ratio 5
Altman-Z -1.02
F-Score4
WACC11.3%
ROIC/WACCN/A
Cap/Depr(3y)407.44%
Cap/Depr(5y)256.94%
Cap/Sales(3y)13.48%
Cap/Sales(5y)8.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.03%
EPS Next Y11.83%
EPS Next 2Y14.26%
EPS Next 3Y13.57%
EPS Next 5Y12.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.58%
Revenue Next Year-1.43%
Revenue Next 2Y0.64%
Revenue Next 3Y1.05%
Revenue Next 5Y18.5%
EBIT growth 1Y21.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.32%
EBIT Next 3Y4.22%
EBIT Next 5YN/A
FCF growth 1Y58.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.12%
OCF growth 3YN/A
OCF growth 5YN/A

ENANTA PHARMACEUTICALS INC / ENTA FAQ

What is the fundamental rating for ENTA stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENTA.


What is the valuation status for ENTA stock?

ChartMill assigns a valuation rating of 0 / 10 to ENANTA PHARMACEUTICALS INC (ENTA). This can be considered as Overvalued.


Can you provide the profitability details for ENANTA PHARMACEUTICALS INC?

ENANTA PHARMACEUTICALS INC (ENTA) has a profitability rating of 1 / 10.


Can you provide the financial health for ENTA stock?

The financial health rating of ENANTA PHARMACEUTICALS INC (ENTA) is 4 / 10.


What is the expected EPS growth for ENANTA PHARMACEUTICALS INC (ENTA) stock?

The Earnings per Share (EPS) of ENANTA PHARMACEUTICALS INC (ENTA) is expected to grow by 11.83% in the next year.